Pivotal efficacy and safety studies meet primary endpoints
VALENCIA, Calif., Dec. 4 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD) today announced that it has met the primary endpoints of its
final two pivotal Phase 3 studies of AFRESATM, the company's ultra rapid
acting, inhaled insulin product. The company expects to disclose more details
of the top-line data from these studies in patients with type 1 and type 2
diabetes (studies 030 and 102) by mid-December.
"We are very pleased to announce the positive outcome of these, the last
of our three pivotal Phase 3 studies. We look forward to presenting more
complete data, including analyses of secondary endpoints, as soon as they are
available, which are expected before the end of this year. AFRESA promises to
be an important additional option for the treatment of patients with diabetes.
Our next step is to finalize a new drug application for AFRESA, which we
expect to submit to the FDA in early 2009," commented Dr. Peter Richardson,
MannKind's chief scientific officer.
About Study 030
Study 030 compared the pulmonary safety of meal-time inhalation of AFRESA
versus usual care in over 2000 patients with type 1 and type 2 diabetes. The
study met its primary endpoint: after two years of treatment, no adverse
effects were observed on patients' lungs in the AFRESA-treated group.
About Study 102
Study 102 compared the efficacy of meal-time AFRESA in combination with a
long-acting basal insulin versus twice daily injections of pre-mixed insulin
(a mixture of a rapid-acting insulin analog and intermediate-acting insulin).
Study 102 met its primary endpoint, showing comparable improvements in HbA1c
levels over 52 weeks between the two treatment groups.
Afresa is an ultra rapid acting inhaled insulin product that has completed
Phase 3 trials. The pharmacokinetic profile of Afresa sets it apart from all
other insulin products. The large surface area of the lung provides unique
access to the circulatory system. The pH-sensitive Afresa particles
immediately dissolve upon contact with the lung surface, releasing insulin
monomers that rapidly enter the bloodstream. It achieves peak insulin levels
within 12-14 minutes of administration, effectively mimicking the release of
meal-time insulin observed in healthy individuals, but which is absent from
patients with diabetes.
About MannKind Corporation
MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development
and commercialization of therapeutic products for patients with diseases such
as diabetes and cancer. Its pipeline includes AFRESA, which has completed
Phase 3 clinical trials, and MKC253, which is currently in phase 1 clinical
trials. Both of these investigational products are being evaluated for their
safety and efficacy in the treatment of diabetes. MannKind maintains a website
at http://www.mannkindcorp.com to which MannKind regularly posts copies of its
press release as well as additional information about MannKind. Interested
persons can subscribe on the MannKind website to email alerts that are sent
automatically when MannKind issues press releases, files its reports with the
SEC or posts certain other information to the website.
This press release contains forward-looking statements, including
statements related to the promise for AFRESA, next steps in the Company's
clinical trial program, plans and timing for the submission of a new drug
application and expectations regarding potential position and use of AFRESA in
the market. Words such as "believes", "anticipates", "plans", "expects",
"intend", "will", "goal", "potential" and similar expressions are intended to
identify forward-looking statements. These forward-looking statements are
based upon MannKind's current expectations and involve risks and
uncertainties. Actual results and the timing of events could differ materially
from those anticipated in such forward-looking statements as a result of these
risks and uncertainties, which include, without limitation, risks related to
the progress, timing and results of clinical trials, difficulties or delays in
seeking or obtaining regulatory approval, MannKind's ability to enter into any
collaborations or strategic partnerships, MannKind's ability to raise
additional financing and other risks detailed in MannKind's filings with the
Securities and Exchange Commission, including the Annual Report on Form 10-K
for the year ended December 31, 2007 and periodic reports on Form 10-Q and
Form 8-K. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this press
release. All forward-looking statements are qualified in their entirety by
this cautionary statement, and MannKind undertakes no obligation to revise or
update any forward-looking statements to reflect events or circumstances after
the date of this news release.
SOURCE MannKind Corporation
CONTACT: Matthew J. Pfeffer, Corporate Vice President and Chief
Financial Officer of MannKind Corporation, +1-661-775-5300,
Web Site: http://www.mannkindcorp.com